Back to search
FDAFDA · Food and drugs·Recall number D-0441-2023

Metformin hydrochloride Extended-Release Tablets, 1000 mg, 60-count bottle, RX only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA, NDC 00591-2720-60

Published March 15, 2023 · Recall initiated: February 22, 2023

Summary

FDA records drug Class II recall D-0441-2023, published March 15, 2023 and initiated February 22, 2023. Recalling firm: Teva Pharmaceuticals USA Inc; Status: Terminated; Reported quantity: 12,044 Bottles; Lot: Lot #: 1410946A; Exp. 06/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA Inc
Distributor
CA
Lot
Lot #: 1410946A; Exp. 06/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Metformin hydrochloride Extended-Release Tablets, 1000 mg, 60-count bottle, RX only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314 USA, Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054 USA, NDC 00591-2720-60 recalled?

Yes. FDA published recall D-0441-2023 on March 15, 2023. Reported hazard: CGMP Deviations: Detection of N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit.

What should I do if I have this product?

Voluntary: Firm initiated · Letter